Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Running, not enrolling · Phase 2

Conditions studied: Breast Cancer, Head and Neck Cancer

In brief

The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).

Key facts

Study ID

NCT05226871

Run by

Pfizer

People needed

35

Starts

2022-07-07

Expected to finish

2026-12-31

Last updated by the study team

2025-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study
• Participants must agree to follow the reproductive criteria
• Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol

You may not qualify if…

• Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study

Where it is running

• UCSF Medical Center at Mission Bay — San Francisco, California, United States
• The First Affiliated Hospital of Anhui Medical University — Hefei, Anhui, China
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China
• Sun Yat-sen Memorial Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
• Henan Cancer Hospital — Zhengzhou, Henan, China
• Hubei Cancer Hospital — Wuhan, Hubei, China
• The First Hospital of Jilin University — Changchun, Jilin, China
• Liaoning Cancer Hospital and Institute — Shenyang, Liaoning, China
• The First Hospital of China Medical University — Shenyang, Liaoning, China
• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China
• Cancer Hospital Chinese Academy of Medical Science — Beijing, China
• Hospital Universitario "Dr. Jose Eleuterio Gonzalez" — Monterrey, Nuevo León, Mexico
• National Cancer Center — Goyang-si, Gyeonggi-do, South Korea
• Samsung Medical Center — Seoul, Seoul-teukbyeolsi [seoul], South Korea
• Seoul National University Hospital — Seoul, South Korea
• National Cheng Kung University Hospital — Tainan, Taiwan
• Mackay Memorial Hospital — Taipei, Taiwan
• Faculty of Medicine, Ramathibodi Hospital, Mahidol University — Ratchathewi, Bangkok, Thailand
• Department of Medicine, Faculty of Medicine Siriraj Hospital — Bangkok, Thailand
• Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" — Chernivtsi, Chernivetska Oblast, Ukraine
• Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council — Dnipro, Ukraine
• Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council — Ivano-Frankivsk, Ukraine

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.